|

Encorafenib + Binimetinib Clinical Trials

2 actively recruiting trials

Pipeline

Phase 2: 1

Top Sponsors

  • Pierre Fabre Ltd1
  • Grupo Español Multidisciplinar de Melanoma1

Indications

  • Cancer2
  • Melanoma and Brain Metastases1
  • Melanoma BRAF V600E/K Mutated1
  • Metastatic Melanoma, BRAF V600 Mutation Positive1

Other2 trials

Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases
Phase 2
UK ENcorafenib and BInimetinib Real-world Study in Melanoma

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.